Lisuride free base | CAS#18016-80-3 | dopamine D2 agonist

MedKoo Cat#: 598995 | Name: Lisuride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lisuride is an ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).

Chemical Structure

Lisuride

CAS#18016-80-3 (free base)

Theoretical Analysis

MedKoo Cat#: 598995

Name: Lisuride

CAS#: 18016-80-3 (free base)

Chemical Formula: C20H26N4O

Exact Mass: 338.2107

Molecular Weight: 338.45

Elemental Analysis: C, 70.98; H, 7.74; N, 16.55; O, 4.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

18016-80-3 (free base) 19875-60-6 (maleate)

Synonym

Lisurid; Lisuride; Lysuride; Mesorgydine; Methylergol; carbamide; N-(D-6-Methyl-8-isoergolenyl)-N′,N′-diethylurea;

IUPAC/Chemical Name

1,1-diethyl-3-((6aR,9S)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl)urea

InChi Key

BKRGVLQUQGGVSM-KBXCAEBGSA-N

InChi Code

BKRGVLQUQGGVSM-KBXCAEBGSA-N

SMILES Code

O=C(N[C@@H](C=C12)CN(C)[C@]1([H])CC3=CNC4=C3C2=CC=C4)N(CC)CC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 338.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zweckberger K, Simunovic F, Kiening KL, Unterberg AW, Sakowitz OW. Effects of lisuride hydrogen maleate on pericontusional tissue metabolism, brain edema formation, and contusion volume development after experimental traumatic brain injury in rats. Neurosci Lett. 2011 Jul 25;499(3):189-93. doi: 10.1016/j.neulet.2011.05.059. Epub 2011 May 30. PubMed PMID: 21658430. 2: Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, Kleinberg D. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa. Neurology. 1981 Aug;31(8):961-5. PubMed PMID: 7022259. 3: Allain H, Destée A, Petit H, Patay M, Schück S, Bentué-Ferrer D, Le Cavorzin P. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol. 2000;44(1):22-30. PubMed PMID: 10894991. 4: Zweckberger K, Simunovic F, Kiening KL, Unterberg AW, Sakowitz OW. Anticonvulsive effects of the dopamine agonist lisuride maleate after experimental traumatic brain injury. Neurosci Lett. 2010 Feb 12;470(2):150-4. doi: 10.1016/j.neulet.2009.12.075. Epub 2010 Jan 5. PubMed PMID: 20056133. 5: Hümpel M, Nieuweboer B, Hasan SH, Wendt H. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level. Eur J Clin Pharmacol. 1981;20(1):47-51. PubMed PMID: 7308272. 6: Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, Nakagawa H. [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants]. Nihon Yakurigaku Zasshi. 1989 Jul;94(1):81-9. Japanese. PubMed PMID: 2792964. 7: Bohnet HG, Hanker JP, Horowski R, Wickings EJ, Schneider HP. Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders. Acta Endocrinol (Copenh). 1979 Sep;92(1):8-19. PubMed PMID: 386688. 8: Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl). 2002 Oct;164(1):93-107. Epub 2002 Jul 19. PubMed PMID: 12373423. 9: LeWitt PA, Burns RS, Calne DB. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. Adv Neurol. 1983;37:131-40. PubMed PMID: 6344586. 10: Kim M, Lee S, Cho J, Kim G, Won C. Dopamine D3 receptor-modulated neuroprotective effects of lisuride. Neuropharmacology. 2017 May 1;117:14-20. doi: 10.1016/j.neuropharm.2017.01.022. Epub 2017 Jan 25. PubMed PMID: 28131770. 11: Bayülkem K, Erişir K, Tuncel A, Bayülkem B. A study on the effect and tolerance of lisuride on Parkinson's disease. Adv Neurol. 1996;69:519-30. PubMed PMID: 8615174. 12: Potter DE, Ogidigben MJ, Chu TC. Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. Pharmacology. 1998 Nov;57(5):249-60. PubMed PMID: 9742290. 13: Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand. 1992 Dec;86(6):593-5. PubMed PMID: 1481646. 14: Nappi G, Martignoni E, Horowski R, Pacchetti C, Rainer E, Bruggi P, Runge I. Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurol Scand. 1991 Jun;83(6):407-10. PubMed PMID: 1909485. 15: Huang J, Gong Q, Huang C, Li G. Relationships between serotoninergic system and skin fibrotic. Antiinflamm Antiallergy Agents Med Chem. 2014 Mar;13(1):9-16. Review. PubMed PMID: 23909604. 16: Rojanasakul A, Sirimongkolkasem R, Chailurkit LO. The efficacy of lisuride in the treatment of hyperprolactinemic amenorrhea. J Med Assoc Thai. 1990 Feb;73 Suppl 1:42-6. PubMed PMID: 2351912. 17: Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med. 2006 Jan;7(1):31-5. Epub 2005 Sep 27. PubMed PMID: 16194624. 18: Schmidt LG, Kuhn S, Smolka M, Schmidt K, Rommelspacher H. Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):209-17. PubMed PMID: 11817496. 19: Chouza C, Caamaño JL, de Medina O, Aljanati R, Scaramelli A, Romero S. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease. J Neural Transm Suppl. 1988;27:61-70. PubMed PMID: 3042913. 20: Fink H, Morgenstern R. Locomotor effects of lisuride: a consequence of dopaminergic and serotonergic actions. Psychopharmacology (Berl). 1985;85(4):464-8. PubMed PMID: 2991961.